RxDoctor Payments Data

Sandra Krasnopolsky, NP

Nurse Practitioner · Hazard, KYNPI 1730250242

Payments from drug & device makers

$3,012in general payments, 2019–2025

Across 180 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$541
  • Johnson & Johnson$518
  • AbbVie$318
  • Otsuka America Pharmaceutical, Inc.$295
  • Alkermes, Inc.$262
  • Takeda Pharmaceuticals U.S.A., Inc.$241
  • plus $837 from 16 others

What the payments were for

  • Food & beverage$3,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,012 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$951
Medicare patients
16
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl31$31,546
VraylarCariprazine Hcl11$16,000
TrintellixVortioxetine Hydrobromide16$10,443
Buspirone Hcl125$2,272
Venlafaxine Hcl ErVenlafaxine Hcl18$1,497
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$991
Aripiprazole34$898
Hydroxyzine Hcl57$826
Gabapentin85$687
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$618
Albuterol Sulfate HfaAlbuterol Sulfate18$599
Fluoxetine Hcl55$583
Bupropion XlBupropion Hcl42$512
Hydroxyzine Pamoate50$475
Mirtazapine52$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$518$31,54631 claims
AbbVieVraylar$318$16,00011 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$241$10,44316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →